come to my notice, 1 will enquire into them. I shall protect the honest officers. I will not protect any corrupt officer, but, at he same time. I will not allow the general morale to go down. What happens is this. Suppose somebody loses a tender, then he spreads all sorts of stories. Letters are sent to me. We examine those things thoroughly.

Secondly, we permit the purchase of tender documents by anybody. Anybody can come and purchase on behalf of somebody else. When we discuss the price bid only the authorised representative of that company is allowed. That is an international practice. They must have some representative. We do. not take others into confidence. We do not allow any discussion with anybody who is not an authorised representative.

**श्री सत्य प्रकाश मालवीय** : मान्यवर, माननीय मंत्री जी बताने की कृपा करें कि पिछले 2 सालों के अंदर खरीदारी के संबंध में अनुमानत: कितनी शिकायतें ओ.एन.जी.सी. को प्राप्त हुई और इस संबंध में क्या-क्या कार्यवाही की गयी?

**श्री बूटा सिंह** : इसके लिए तो मुझे सूचना एकत्रित करनी पड़ेगी। कितनी शिकायतें प्राप्त हुई हैं और क्या एक्शन हुआ, इस समय सूचना मेरे पास उपलब्ध नहीं है मैं माननीय सदस्य को भेज दूंगा।

**श्री सत्य प्रकाश मालवीय** : जो मूल प्रश्न है इसी से संबंधित है। उन्हें इतनी तो जानकारी होनी चाहिए कि कितनी शिकायतें प्राप्त हुई।

**Sales turn-over of Ascorbic Acid**

*125. DR. RATNAKAR PANDEY: -!

SHRI RAJNI RANJAN SAHU:

Will the Minister of INDUSTRY be pleased to stale:

(a) whether it is a fact that Ascorbic Acid has been price-decontrolled;

(b) if so, whether it is also a fact that the main criterion for exclusion of drugs from price control are (i) -that production structure should be competitive and (ii) the annual sales turn-over should be less than rupees fifty lakhs;

(c) whether it is also a fact that the annual sales turn-over of this drug is more than rupees fifty lakhs and this drug is a monopoly production;

(d) what was the sales turn-over of \ Ascorbic Acid during the year, 1986;

(e) what are the names of producers of this drug alongwith their licensed and installed capacity and production during the last three years, year-wise; and

(f) on what grounds Ascorbic Acid has been removed from the list of priae controlled drugs ?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO); (a) to (f). A Statement is laid on the Table of the Rajya Sabha.

Statement

Yes, Sir.

lb) The various criteria for exclusion of drugs from the list of Category-II d for price control are given in the Kelkar Committee Report, copies of which are available in the Parliament Library.

(c) and (d) Ascorbic Acid/Sodium Ascorbate is being produced by two companies only. Sales turnover of bulk drugs/ formulations is not monitored.

(e) The required details, to the extent available, are given in the Annexure (See below).

(f) The Kelkar Committee had recommended that all Vitamins when used in combinations in formulations should come under Category-II of price control. Hence all vitamins as bulk drugs including Ascorbic Acid have been exempted from price control.

actually asked on the floor of the House by Dr. Ratnakar Pandey.

Annexure

| SI. No. | Name ofthe Company | A/C Unit | Licensed LCapacity | Installed Capacity | 1984-1985 | Production 1985-1984 | 1936-1987 |
|---|---|---|---|---|---|---|---|
| 1. | M/s. Jayant Vitamins | T | 770. 5 | N. A. | 455. 44 | 369. 01 | 593. 6 |
| 2. | M/s. S'uablvU M. Chemicals | r | 240. 0 | N. A. | 260. 79 | 282. 25 | 180. 38 |

SHRI JAGESH DESAI: Mr. Chairman, Sir, we want your protection. The manner in which the answer is given to the question is very casual. In part (b), it was asked whether it is also a fact that the main criterion for exclusion of drugs from price control are...

MR. ' CHAIRMAN: Leave it to the questioner...

SHRI JAGESH DESAI: My point is this. He says the copies are available in the Parliament Library...

MR. CHAIRMAN: He can take care of himself. He does not need any help.

**डा. रत्नाकर पाण्डेय** : माननीय सभापति जी, विटामिन ''सी'' का प्रयोग अत्यंत आवश्यक जीवन मूल की दवाओं में होता है और मंत्रालय ने यह स्वीकार किया है कि जो इस प्रकार के भेषज की कुल वार्षिक बिक्री 50 लाख से अधिक होती है उसका एकाधिकार उत्पादन होता है। जो उत्तर दिया गया है उसमें साफ लिखा है कि :

"The various criteria for exclusion of drugs from the List of Category-II drugs for price control are given in the Kelkar Commttee Report, copies of which are available in the Parliament Library. Ascorbic Acid/Sodium Ascor-bate js being produced by two companies only. "

वे दो कम्पनियां जो हैं एक तो जयंत विटामिन्स है दूसरी है मैसर्स साराभाई एम. केमिकल्स और पिछली बार 5 करोड़ 93 लाख का एक ने और 1 करोड़ 80 लाख का एक ने प्रोडक्शन किया है जबकि 50 लाख रुपये तक ही हम नियंत्रण में रखते हैं उससे कम उत्पादन करने वाला। तो इन दोनों कम्पनियों को जो अनिवार्य, जीवन की आवश्यकतापूर्ण दवाएं हैं, उस नियम से क्यों हम परे रख रहे हैं? क्या, इसमें सरकार की पालिसी है, किस कारण इनको छूट दी गयी है?

SHRI J. VENGAL RAO: Sir in my statement I mentioned that vitamins as bulk drugs including Ascorbic Acid have been exempted from price control. The Kelkar Committee had recommended that all vitamins when used in combinations in formulations should come under Category-II. Sir, if they are using this in other combinations, it will come under Category-II.

**डा. रत्नाकर पाण्डेय** : सभापति महोदय केलकर समिति की रिपोर्ट की चर्चा की गयी है, क्या मंत्री महोदय उस सदन में लायेंगे और आवश्यक जीवन मूल्य की जो दवाएं हैं या अन्य भेषजों से संबंधित रिपोर्ट में जो अनुशंसाएं की गयी हैं सदन उन पर बहस करके कोई निश्चय करके अपनी मोहर लगा दे इस पर मंत्री जी का क्या विचार है, क्या उन्होंने सोचा है, क्या इस तरह का प्रावधान वे करेंगे?

SHRI J. VENGAL RAO: Sir, I have no objection. If the House wants to discuss on this Report, I will certainly aeree for it.

**श्री रजनी रंजन साहू** : माननीय सभापति महोदय, यह कहने की आवश्यकता नहीं है कि नयी दवा नीति की अनेक मायावी विशेषताएं हैं। एक ही साथ कीमत बढ़ाने में मदद कर गरीब उपभोक्ताओं की जान लेने वाली नीति है। दूसरी ओर बड़े उद्योगपतियों को, जो दवा से संबंधित हैं उन्हें अरबपति से खरबपति बनाने की नीति है और सबसे बड़ी बात है कि मल्टी नेशनल कम्पनियां जो भी उस देश में हैं उन्हें एन: ईस्ट इंडिया कम्पनी की तरह फैलाने में मदद यह नीति कर रही है। नयी दवा

नीति के बाद अपने प्रेस वक्तव्य में मंत्री जी ने जो कहा और जो यह नयी नीति का रूप है इसमें अनेक फर्क हैं। तो इसमें मैं मंत्री महोदय से जानना चाहूंगा कि 1979 की दवा नीति में जब विटामिन सी के सभी इनग्रीडिएंट्स पर कंट्रोल था, तो 1986 की नीति में विटामिन सी के सभी इनग्रीडिएंट्स पर जो बल्क के इनग्रीडिएंट्स हैं उन पर कंट्रोल क्यों नहीं रखा गया ? जब आप उसके बल्क इनग्रीडिएंट्स पर कंट्रोल नहीं रख सकेंगे, तो मंत्री महोदय से पूछना चाहूंगा कि क्या जो फिनिश्ड ड्रग हैं, उस पर कैसे कंट्रोल रख सकेंगे?

यह मेरा प्रश्न "ए" है। दूसरा प्रश्न "बी" है कि नई दवा नीति के पूर्व यह नियम था कि केटेगरी I की दवायें स्वास्थ्य विभाग की अनुशंसा पर रखा जाएगा यानी स्वास्थ्य विभाग नेशनल हैल्थ प्रोग्राम के अनुरूप डिजीज स्पेसिफाई करेगी और उन्हीं के मुताबिक दवा केटेगरी I में रखी जाएगी, और इसी आधार पर कमेटी का रेकोमेंडेशन होना चाहिए था, मैं जानना चाहूंगा कि किस आधार पर जिन दवाओं को केलकर कमेटी ने केटेगरी I के लिए अनुशंसा की और उन्हें मंत्रालय ने यह जानते हुए कि यह बीमारी और उसके लिए दवा नेशनल हैल्थ प्रोग्राम के आश्रित है, उसे केटेगरी II में रख दिया।

इतना ही नहीं केलकर कमेटी उन सभी दवाओं का जिसका उत्पादन 50 लाख से ज्यादा है, उसे प्राईस कंट्रोल में रखा जाए, ऐसी अनुशंसा की, पर किन वजहों से उसका, जिनका उत्पादन जैसा कि सदन के पटल पर रखा गया है, उत्पादन 593 और 180 है, उसे प्राईस कंट्रोल में नहीं रखा गया है।

क्या यह डिस्क्रिमिनेशन नहीं है और क्या यह संविधान की धारा 14 का कंट्रावेन्शन नहीं है?

मैं इन दो बातों पर मंत्री महोदय का उत्तर चाहूंगा।

SHRI J. VENGAL RAO: Sir, he has asked so many questions in one question. In category I there are 27 drugs. These 27 drugs were selected by the Minister of Health and Family Welfare. We have no objection to include more. These are life-saving drugs which are useful to common man. We cannot deviate. These 27 drugs we have to maintain in category I. Regarding category II if the Members have any suggestions the hon. Members can send them to me and I will ask the Kelkar Committee to go into it and include them in category II.

SHRI RAINI RANJAN SAHU: Sir, my question is very simple. I want to know whether his Ministry has gone against the recommendations of the Kelkar Committee or not.

MR. CHAIRMAN: That is his question. He says whatever was put in category I, you have changed and put it in category II.

SHRI J. VENGAL RAO: In toto we have accepted the recommendations of the Kelkar Committee. If there are any difficulties or if there are any drawbacks, I will request the Members to make their suggestions and I will again ask the Kelkar Committee to look into it.

SHRI RAJNI RANJAN SAHU: Why

**श्री सभापति** : वह कह रहे हैं कि उसे पूरा मान लिया है और अगर कोई और खामी है, तो आप बता दीजिए ।

there is discrimination with these two companies when the Kelkar Committee has said that the turn over of fifty lakhs should be put under the category of price control and when there is a turn over of rupees five hundred ninety three lakhs and one hundred and eighty lakhs has not been included in list of Price Control ? Why it has not been brought under price control'. '

SHRI J. VENGAL RAO: Sir, these two companies are manufacturing only 773. 98 tonnes of this acid. Our demand is for 1. 050 tonnes. But we are producing less than the demand.

SHRI RAJNI RANJAN SAHU: Sir, he is not clear in- his reply;

MR. CHAIRMAN: Now he has explained to you.

SHRI JAGESH DESAI: Mr. Chairman, Sir, first of all, I want your protection. In i part (b) of the question it has been asked' whether it is also a fact that the main criterion for exclusion of drugs from price control are (i) that production structure should be competitive and (ii) the annual sales turn-over should be less than Rs. 50 lakhs. These were the basic two aspects on which the Members wanted to know. And the Minister's reply is...

MR. CHAIRMAN: You ask your question.

SHRI JAGESH DESAI:... that we should go to the Library and see the Kelkar Committee's Report. It is like suggesting to me to go and look into the Seventh Five Year Plan if I ask a question on- the Seventh Five Year Plan. Sir, I want your protection. The Minister should come with specific answers to the specific questions that are asked. They should not treat the questions casually but reply to our questions.

श्री लाल कृष्ण आडवाणी : सभापति जी, यह अपना उत्तर दें लेकिन उससे पहले जो मूल सवाल उठा है उस पर आपकी रूलिंग चाहिए, क्योंकि यह परंपरा बन जाएगी और यह इस प्रकार कह देंगे कि आप जाकर लायब्रेरी में देखिए । यह कोई जवाब है ? यह भी कहने को तैयार नहीं कि गलत जवाब है । सभापति जी, परंपरा सही होनी चाहिए

SHRI PAWAN KUMAR BANSAL: The Minister can answer and say 'yes' or 'no' instead of saying that we should refer to Kelkar Committee's Report in the Library.

SHRI J. VENGAL RAO: Kelkar Committee's Report is in the Library. That is why we referred to it.

SHRI JAGESH DESAI: I wanted to ask a supplementary on these two aspects and my right to get an answer has been taken away.

SHRI J. VENGAL RAO: Whatever they want, I agree. If they want a discussion on it. T ntrree to it.

SHRI LAL K. ADVANI: There is no queslion of a discussion.

MR. CHAIRMAN: Members want that their questions should be answered and what they say is correct also. You cannot tell them that they should go to the library and see the Report. You must come up with answers. If you'are not prepared today. I will put it for the next day.

SHRI J. VENGAL RAO: Voluminous report is prepared...

SHRI MURLIDHAR CHANDRAKANT BHANDARE: That is not the point fit nil.

SHRI J. VENGAL RAO: If you want, I will place it on the Table of the House; 1 have no objection.

श्री रजनी रंजन साहू : सभापति जी, मेरा अनुरोध है कि इस पर आधे घंटे की बहस की अनुमति दी जाए, क्योंकि जो क्वेश्चन है उसका उत्तर नहीं दे रहे हैं ।

SHRI ARUN SINGH: Half-an-hour discussion on the Kelkar Committee Report has nothing *to* do with Minister's reply in Parliament. They cannot ask Members to refer to Parliament Library; otherwise every Ministry will say, you go to Library.

SHRI MURLIDHAR CHANDRAKANT BHANDARE: There are two questions. One is that production structure should be competitive. There is no answer to that. Why should he refer to Library ? The Minister must tell us whether that is one of th© criteria. The second is that the annual turnover should be less than Rs. 50 lakhs. What is the difficulty in answering these two questions?" Why refer to Committee's Report?

MR. CHAIRMAN: You must take the feelings of the Members of the House and give adequate answers. We can have it on the next day. You should come with adequate answers and with adequate preparation.

SHRI J. VENGAL RAO: My answer is not inadequate. They want more information.

SHRI N. E. BALARAM: I do not know the recommendations made by the Kelkar Committee because I did not go to the Library. I would like to know from the hon. Minister whether by a recent order, prices of some of the life-saving drugs have already been increased. This has created great difficulties for the common people. Will the Government reconsider this question. This is my point.

SHRI J. VENGAL RAO: We are considering this question. We will bring them tinder the Drug Price Control Order, under Category II. We will reduce the price.

SHRl N. E. BALARAM: That is not my point. I said, Government, by a recent order, increased the prices of some of the most important life-saving drugs. Are you prepared to reconsider that question. I am not talking about the whole thing. I am talking about the recent Government order.

§HRI VASANT SATHE: This question can again be brought up.

MR. CHAIRMAN: I have said that we are putting it up for the next week. Then you can put youY supplementaries (*Interruptions)*

अगले सप्ताह में इसको ले रहे हैं, तब ले लीजिए। पोस्टपोन कर दिया है सवाल, अगले सप्ताह के लिए।

*126. *[The questioner (Shri Harvendra Singh Hanspal) was absent. For answers,* vide *col.* 29, infra. ]

**Outlay on H. B. J. Pipeline**

*127. SHRI SHANKER SINH VAGHELA: Will the Minister of PETROLEUM AND NATURAL GAS be pleased to state:

(a) whether the work of laying of HBJ Pipeline has suffered considerable delay, if so, the details of the delay suffered so

(b) what was the total outlay for the laying of this pipeline and how far it is likely to exceed the original estimate; and

(c) apart from Gujarat, what are the other projects it is likely to serve, Statewise ?

THE MINISTER OF STATE OF THE MINISTRY OF PETROLEUM AND NATURAL GAS (SHRI BRAHM DUTT: (a) No, Sir. There is no delay in laying of HBJ Gas Pipeline.

(b) The total approved and estimated outlay for the pipeline is Rs. 1700. 17 crores and this original estimate is not likely to be exceeded.

(c) Apart from Gujarat, gas will be supplied to the following units in the various States through which the HBJ Pipeline passes.

| States | Fertilizer Power Plants |
|---|---|
| Rajasthan | one Power Plant<br>one Fertilizer Plant |
| Madhya Pradesh | one Fertilizer Plant |
| Uttar Pradesh | one Power Plant<br>Four Fertilizer Plants |

**श्री शंकर सिंह वाघेला** : चेयरमैन सर, मिनिस्टर साहब ने जवाब दिया है कि इसमें कोई डिले नहीं होगी. वाकई में एसोरेंस चाहेंगे कि डिले नहीं होगी फेजवाइज और सेक्टरवाइज । दूसरा, जिस इण्टेन्सन से पाइप-लाइन को गुजरात में से लेकर गैस ली जा रही है, आयल लिया जा रहा है, छह फर्टिलाइजर प्लांटस के बारे में आपने कहा है । तो क्या आज यह छह फर्टिलाइजर प्लांट्स के परपोजलस, जिनमें फर्टिलाइजर प्लांट करने को कहा था, यह स्टेंडस्टील आज भी है ? वर्धराजन हाई पावर कमेटी ने जो यह रिकमण्ड किया है, फर्टिलाइजर प्रोडक्शन करने का कोई मतलब नहीं है, तो यह छह के छह आज भी मौजूद हैं ? इस हिसाब से पाइप-लाइन समय पर पूरी होगी और एस्टी-मेट नहीं बढ़ेगा इसका आश्वासन देंगे ?